Clinical potential of oligonucleotide-based therapeutics in the respiratory system

Sterghios A. Moschos, Louise Usher, Mark A. Lindsay

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
258 Downloads (Pure)

Abstract

The discovery of an ever-expanding plethora of coding and non-coding RNAs with nodal and causal roles in the regulation of lung physiology and disease is reinvigorating interest in the clinical utility of the oligonucleotide therapeutic class. This is strongly supported through recent advances in nucleic acids chemistry, synthetic oligonucleotide delivery and viral gene therapy that have succeeded in bringing to market at least three nucleic acid-based drugs. As a consequence, multiple new candidates such as RNA interference modulators, antisense, and splice switching compounds are now progressing through clinical evaluation. Here, manipulation of RNA for the treatment of lung disease is explored, with emphasis on robust pharmacological evidence aligned to the five pillars of drug development: exposure to the appropriate tissue, binding to the desired molecular target, evidence of the expected mode of action, activity in the relevant patient population and commercially viable value proposition.

Original languageEnglish
Pages (from-to)83-103
JournalPharmacology and Therapeutics
Volume169
Early online date19 Oct 2016
DOIs
Publication statusPublished - Jan 2017

Keywords

  • Delivery
  • MiRNA
  • Oligonucleotide therapeutics
  • PNA
  • PPMO
  • SiRNA

Fingerprint Dive into the research topics of 'Clinical potential of oligonucleotide-based therapeutics in the respiratory system'. Together they form a unique fingerprint.

Cite this